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Abstract
Background and Aims: Legalization of cannabis (CB) for both medicinal and, in some states, recreational use,
has given rise to increasing usage rates across the country. Of particular concern are indications that frequent CB
use may be selectively harmful to the developing adolescent brain compared with adult-onset usage. However,
the long-term effects of heavy, adolescent CB use on brain structure and cognitive performance in late-life re-
main unknown. A critical brain region is the hippocampus (HC), where there is a striking intersection between
high concentrations of cannabinoid 1 (CB1) receptors and age-related pathology.
Design: We investigated whether older adults (average age = 66.6 + 7.2 years old) with a history of early life CB
use show morphological differences in hippocampal subregions compared with older, nonusers.
Methods: We performed high-resolution magnetic resonance imaging combined with computational techniques
to assess cortical thickness of the medial temporal lobe, neuropsychological testing, and extensive drug use histo-
ries on 50 subjects (24 formerly heavy cannabis users [CB+ group] abstinent for an average of 28.7 years, 26 non-
users [CB group]). We investigated group differences in hippocampal subregions, controlling for age, sex, and
intelligence (as measured by the Wechsler Test of Adult Reading), years of education, and cigarette use.
Results: The CB+ subjects exhibited thinner cortices in subfields cornu ammonis 1 [CA1; F(1,42)= 9.96, p= 0.0003],
and CA2, 3, and the dentate gyrus [CA23DG; F(1,42)= 23.17, p< 0.0001], and in the entire HC averaged over all sub-
regions [F(1,42)= 8.49, p= 0.006].
Conclusions: Negative effects of chronic adolescent CB use on hippocampal structure are maintained well into
late life. Because hippocampal cortical loss underlies and exacerbates age-related cognitive decline, these find-
ings have profound implications for aging adults with a history of early life usage.
Clinical Trial Registration: ClinicalTrials.gov # NCT01874886.
Keywords: hippocampus; magnetic resonance imaging; high-resolution; cortical thickness
Introduction
Marijuana (Cannabis sativa) is the most widely used
‘‘illicit’’ drug worldwide, with an estimated 183 million
past-year users worldwide,1 over 20 million Americans
reporting previous month use, and 4.6 million Ameri-
cans meeting criteria for dependence in 2015.2 Adoles-
cent cannabis (CB) use is particularly concerning given
the vulnerability of the adolescent brain.3 Since brain
development continues throughout young adulthood,4
adolescence may be a critical period during which CB
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exposure may have long-lasting implications.5 In ani-
mal models, the primary psychoactive ingredient in
CB, D9-tetrahydrocannabinol (THC) induces dose-
dependent neurotoxic changes in the brain.6,7 Specific
brain regions affected, including the hippocampus
(HC), amygdala, striatum, and cingulate cortex, have
high densities of cannabinoid 1 (CB1) receptors8 and,
importantly, are among the first brain areas to show
age-related morphological changes.9
For several decades, results regarding whether chronic
CB use damages the brain were mixed.10–13 However,
technological advances in magnetic resonance imaging
(MRI) have enabled findings that chronic CB use has a
significant effect on hippocampal structure in adoles-
cents,5,14–17 and mounting evidence points to cognitive
impairment after heavy CB use.18–21 People who were
adolescents in the 1960s and 70s, when CB use dou-
bled,22 are now entering late life, a period of high risk
for age-related memory and cognitive deficits.23–27 How-
ever, how heavy CB use early in life affects brain struc-
ture and cognitive performance in late life is unknown.
We focused the present investigation on hippocampal
morphology and cognitive performance because the HC
exhibits dense concentrations of CB1 receptors8,28 and
because it is the primary site of age-related changes as-
sociated with memory impairment and dementia.23,24,29
Prior MRI studies have suggested a particularly adverse
effect of CB on the HC during adolescent brain develop-
ment.14 There is also substantial evidence for neuroana-
tomical abnormalities within the HC in CB users.30–32
One study of heavy CB users found smaller volumes
of the HC and amygdala, and provided some of the ear-
liest imaging evidence that heavy, long-term CB use is
harmful to brain tissue.33 In younger subjects (30 years
on average), volumes in hippocampal subregions CA1,
2, 3 and the dentate gyrus (DG) were smaller in depen-
dent CB users than in nonusers,30 but similar data
were not available from older subjects (over the age
of 55) to see whether changes to hippocampal structure
persisted over time.
In this study, ultra-high-resolution MRI data focus-
ing on the HC were obtained and analyzed using a cor-
tical unfolding technique, enabling analysis of cortical
thickness in hippocampal subregions. This technique
has been used to reveal subtle brain differences among
cognitively intact older adults,34–36 to predict decline
in cognition,37 and to show changes in the CA1 in mul-
tiple sclerosis.38
Subregional analysis of the HC has been shown in
other laboratories,39 and ours,34 to be more sensitive
to subtle morphological differences in hippocampal
subregions than volumetric analyses. Additionally,
CB1 receptors are not distributed equally across the
HC but are most densely concentrated in CA2, CA3,
and the DG, followed by CA1 in decreasing order.40
Similarly, cortical thinning in aging is region specific,
with entorhinal cortex (ERC) and CA1 particularly af-
fected.41
As a control to show that brain differences are spe-
cific to regions with high CB1 receptor density, we
also conducted a region of interest (ROI) analysis of
the parietal cortex, a brain region which also exhibits
age-related morphological changes in late life, but
which has a lower CB1 receptor density than the me-
dial temporal lobe (MTL).42 Hippocampal and parie-
tal cortex morphology were therefore compared
between former heavy CB users (‘‘CB + ’’ group) and
control subjects (‘‘CB’’ group). This is the first
study that examines older individuals with a history
of early life CB use to answer questions about the lon-
gitudinal effects of CB use in the aging brain.
Methods
The study was conducted with the approval of the
UCLA IRB; subjects were recruited from the local
community through advertisements in local media re-
sources and signed informed consent forms before par-
ticipating. Subjects were first screened over the phone
and those reporting use of cocaine, methamphetamine,
ecstasy, heroin, or other illicit substances more than
once were excluded. We recruited older subjects (57–
75 years old) with ‘‘significant’’ CB exposure during ad-
olescence (defined as CB use on at least 20 days/month,
initiating use during adolescence (before age 20) and
continuing for at least 1 year with no more than one
to two uses/month after age 35).
We enrolled 24 former heavy CB users (‘‘CB + ’’) and
26 control subjects (‘‘CB’’) who reported never having
used cannabis or any other illicit substances. Participants
also provided a urine sample for biological verification of
abstinence from use of any illicit substances on the day
of neuropsychological testing (Instant-View Multi-
Drugs of Abuse Urine Test; Alfa Scientific Designs,
Inc.). Participants with a history of neurological or psy-
chiatric disorders, engagement in psychological treat-
ment (within the previous 6 months), or current or
past diagnoses of psychotic disorders were excluded
from the study using DSM-V criteria.43
During their visit, participants underwent neuropsy-
chological testing, a clinical interview, a physical and
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medical examination, and laboratory screening, includ-
ing tests to rule out medical conditions that could affect
cognitive performance (e.g., abnormal thyroid or pitu-
itary hormone levels).44,45 Subjects with a history of
uncontrolled hypertension or cardiovascular disease
(systolic blood pressure [BP] >170 or diastolic BP
>100), head trauma, or other major systemic disease
affecting brain function were excluded. Participants
taking medications that could influence psychometric
testing were also excluded.46 Drug use characteristics
were assessed through a semistructured interview
(‘‘Drug Use History;’’ Table 1), which was used to
characterize lifetime and current substance use.
Participants’ self-reported substance use was further
corroborated with an additional measure of substance
use (Timeline Follow Back [TLFB]47). Subjects were
also given the Hollingshead Four-Factor Index of Soci-
oeconomic Status48 to assess the influence of socioeco-
nomic status (SES). Additionally, subjects were given
the Mini-Mental State Examination to assess cognitive
state,49 the Hamilton-D rating scale to assess depres-
sion,50 and the Wechsler Test of Adult Reading
(WTAR) to estimate premorbid intellectual function-
ing.51 Based on the high co-occurrence of CB use
with cigarette smoking and alcohol use, smoking and
light alcohol use (<14 drinks/week for men, <7 drinks/
week for women) were allowed.
Results from the Marijuana Smoking History Ques-
tionnaire (MSHQ)52 were used to create variables of
interest related to CB use, including ‘‘Age of Onset’’
and ‘‘Lifetime Marijuana Use’’ (Average use/week ·
Number of years of use). We investigated the relation-
ship between these variables in CB+ and CB subjects
and MTL subregional thickness. As frequency may be
different over time (i.e., 5 · /year for 2 years, then
1 · /year for 25 years), the Lifetime Marijuana Use
composite score was chosen as the most accurate rep-
resentation of usage over many years.
We divided neuropsychiatric test scores into the fol-
lowing domains of cognitive function: Memory Encod-
ing, Delayed Memory, Processing Speed, and Executive
Functioning (see Fig. 4 for individual tests in each do-
main). Studies using these domains have been reported
elsewhere.37,53–55 Raw scores in each test were first con-
verted to Z scores [Z = (raw score-mean)/standard de-
viation] and then binned together to create a domain
Z score by averaging the Z scores belonging to the cog-
nitive tests in each domain.
All participants underwent a 45-min scan at the 3T
Siemens Trio scanner located in the Center for Cogni-
tive Neuroscience at the Semel Neuropsychiatric Insti-
tute using a 12-channel parallel coil. After scout and
localizer scans were acquired (2min), high-resolution
fast spin echo (FSE) scans of the HC were acquired in
an oblique coronal plane perpendicular to the long axis
of the HC to ensure complete coverage (see Fig. 1a;
FSE, repetition time [TR]= 4800ms, echo time [TE]=
106ms, field of view [FOV] 150, 512· 512, NEX4, 26
Table 1. Drug Abuse Phenotyping (1 h)
Measure Description Variables Duration
No. of
Items
Fagerstrom Test for Nicotine
Dependence70
Self-report assessment (six items) of smoking behavior
(e.g., time to first cig, cigs/day) and dependence.
Smoking behavior,
nicotine dependence
*3min Smokers
only
12
Cigarette Use Timeline
(London Lab, unpublished)
Self-report form. Participant to fill in smoking rates
on a timeline of his/her smoking history.
Used to estimate pack-years.
Cigarettes/day over
the smoking history
5–10min Smokers
only
N/A
Drug Use History
(London Lab, unpublished)
Structured interview utilizing a standard form.
Collects data regarding use of drugs of abuse in all
classes (age at first use, current usage, greatest
regular lifetime usage, and peak usage).
Complete drug
use history
15min 1011
Marijuana Dependence
Checklist71
Self-report questionnaire. Items assess dependence
on cannabis.
Cannabis dependence 2–3min MJ smoker
only
10
Marijuana Smoking History
Questionnaire52
Self-report questionnaire. Collects data regarding
recent and lifetime cannabis use, average amounts
of use and routes of administration. Also asks about
changes in use, and quit attempts.
Cannabis use 1–8min 22
Smoking History Questionnaire
(London Lab, unpublished)
Self-report form. Items relate to benchmarks of
smoking behavior (e.g., age at first cigarette, age
at first 100 cigarettes, longest quit attempt, number
of quit attempts, reasons for quitting)
Data related to
smoking behavior
5min 26
Timeline-Followback Interview47 Interview using memory prompts to determine
substance use for the last 30 days.
Alcohol Use 15min 30
Testing battery used for assessing drug use history for individual subjects. Individual test names are listed along with a description of the test, the
variables tested for, and the duration of the test.
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slices, 2mm thick, 0mm spacing, 400· 400lm in-plane
resolution). This sequence optimizes in-plane resolution,
where the subregional variability is largest, while produc-
ingminimal variability through plane when the slices are
precisely perpendicular to the long axis. We also ac-
quired a Magnetization-Prepared Rapid Acquisition
Gradient Echo (MPRage) scan for excellent gray–white
contrast (T1-weighted volumetric study: TR 2300; TE:
2.93; flip angle 8; FOV 256· 256; bandwidth 210Hz/
px; 1-mm isotropic voxels) for visual reference during
segmentation and ROI analyses.
We used cortical unfolding to improve visualization
of the convoluted MTL cortex by flattening the entire
three-dimensional volume into a two-dimensional flat
map.34,35,56 Methods for high-resolution hippocampal
analysis with unfolding are described in detail else-
where.35 Boundary demarcations divided the follow-
ing subregions encompassed by gray matter: cornu
ammonis (CA) fields 1, 2, and 3, the DG, subiculum
(Sub), ERC, perirhinal cortex, parahippocampal cor-
tex, and the fusiform gyrus (Fus) (Fig. 1b–e). This strip
of gray matter is used as the input for the unfolding
FIG. 1. High-resolution hippocampal image processing and thickness calculations. (A) The goal of high-
resolution hippocampal image processing is to isolate the strip of gray matter in the MTL that encompasses the
subregions of the hippocampus proper and surrounding neocortex, shown in (B) in blue. This is done by
manually segmenting cerebrospinal fluid and white matter and growing sequential layers of gray matter from
the edge of white matter until the layer reach the cerebrospinal fluid boundary. (C) The boundaries between
MTL subregions are marked according to anatomical landmarks. Because of limits in resolution in CA fields 2, 3,
and DG we treat these regions as a single entity (CA23DG). Demarcations shown here include CA fields 2, 3, and
the dentate gyrus (CA23DG) j CA1 (red), CA1 j subiculum (Sub; yellow), PHC j Sub (blue), fusiform gyrus (Fus;
orange), Collateral sulcus (CollSul; purple) and PRC (green). (D) Boundary delineations were projected to their
corresponding coordinates in flat map space. Each subregion is considered separately for cortical thickness
calculations. Cortical thickness is visualized in in-plane space as a grayscale map of thickness values between
maximum (white) and minimum (black) values. (E) To extract thickness, the distance from each voxel in in-
plane space to the nearest nongray matter voxel was calculated. Next, the maximum distance value of two-
dimensional voxels for the corresponding three-dimensional voxels across all layers was taken and multiplied
by two to calculate mean thickness. Demarcations were projected from in-plane space to the corresponding
location in 2D flat map space and then extended to form complete and smooth boundaries between
subregions. CA1, cornu ammonis 1; ERC, entorhinal cortex; PHC, parahippocampal cortex; PRC, perirhinal
cortex; MTL, medial temporal lobe.
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procedure, an iterative algorithm based on multidi-
mensional scaling (http://ccn.ucla.edu/wiki/index.php
/Unfolding). Cortical thickness within subregions was
averaged over both hemispheres. The following formula
was used to normalize hippocampal thickness values
to intracranial volume (ICV) estimates: ICV-corrected
thickness = [(thickness in mm/ICV in mm3) · 106].
Multiplying by 106 results in values at the same order
of magnitude as original thickness estimates.
We used FreeSurfer 6.0 to process T1 MRI scans
(http://surfer.nmr.mgh.harvard.edu). Based on the sta-
tistical maps from the data set, The Open Access Series
of Imaging Studies (OASIS; https://www.oasis-brains
.org), we created an ROI of parietal cortex. For volu-
metric calculations of volume in inferior parietal lobe, we
used FreeSurfer on whole brain T1-weighted scans. After
the automated portion of the FreeSurfer pipeline was
complete, each participant’s scan was visually checked
for accuracy. Minimal manual edits were completed by a
single individual when necessary. ICV values from
FreeSurfer were used to normalize volume in the parietal
lobe volumes. Because FreeSurfer parcellation results in
separate volumes for superior and inferior parietal lobe
volumes, results from the two ROIs were used to create
an average parietal lobe ROI for each subject.
Statistical analyses
Demographic variables between groups were compared
using t-tests for continuous measures and chi-squared
tests for categorical measures. General linear models
were used to test for significant group differences in
thickness for each of the MTL subregions, with sex,
age, WTAR, cigarette use, and education included as
covariates. Differences in neuropsychological perfor-
mance in each domain were also tested with general
linear models, with the same covariates shown
above. A similar model examined differences in the
volumes of parietal lobes between CB+ and CB
groups, controlling for the above covariates as well
as total ICV. In addition to the standard statistics,
we also present effect sizes (ES; Cohen’s d) for all
group differences. Statistical significance was set at
p = 0.05 for all models.
Results
Clinical and demographic characteristics are described
in Table 2. Results from the MSHQ (Table 1) indicated
an average age of onset of 17.7 – 4.2 years of age and
lifetime cannabis use of 11.3 – 13.0 years duration.
Groups did not differ in age, gender, or MMSE scores.
However, the groups differed in number of years of ed-
ucation, cigarette usage, and WTAR performance;
these variables were included as covariates in general
linear models examining differences in the mean be-
tween the two groups.
CB+ subjects had thinner cortex in subfields CA1
[F(1,42) = 9.96, p = 0.003; ES = 0.98] and CA23DG
[F(1,42) = 23.17, p < 0.0001; ES = 1.49] (Fig. 2) and
thinner HC averaged over all subregions [F(1,42)=
8.49, p= 0.006; ES= 0.90] (Fig. 3). WTAR scores were
significantly lower in CB+ subjects [t(47) = 2.24,
p = 0.03], but even after removing the most extreme
values in WTAR (to better match groups on WTAR
performance and ensure that this factor was not
Table 2. Demographic and Clinical Characteristics of Study Participants (mean/n6SD)
Cohort characteristics
CB1 CB Between-group statistics
n= 24 n= 26 t(48)/v2(1), p-value
Mini-Mental State Examination score 28.0– 1.6 28.4– 1.7 0.82, 0.42
Age, years 65.4– 7.2 67.7– 7.1 1.12, 0.27
Educational achievement, years 15.3– 2.0 16.6– 2.3 2.04, 0.05**
Female sex, n (%) 8 (33) 12 (46) 1.92, 0.17
Cigarette smoker, n (%) 14 (58) 7 (27) 5.05, 0.02**
Hamilton Depression Scale score 7.0 – 7.5 4.9– 5.3 1.16, 0.25
WTAR 35.7– 9.6 41.2– 7.4 2.24, 0.03**
Hollingshead coding 5.4 – 1.7 5.8– 1.7 0.92, 0.36
Cannabis use — —
Onset of regular use (age in years– SD) 17.7– 4.2 — —
Duration of use (years– SD) 11.3– 13.0 — —
Lifetime use (days– SD) 4181.2– 4784.6 — —
Length of abstinence (years– SD) 29.9– 6.0 — —
Lifetime alcohol use (no. of standard drinks/month – SD) 21.6– 12.0 19.8– 11.3 0.54, 0.59
**p < 0.05.
SD, standard deviation; WTAR, Wechsler Test of Adult Reading.
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FIG. 3. Subregional cortical thickness in individual subregions for CB+ and CBgroups. CB+ subjects showed
thinner cortex in subfields CA1 [F(1,42)= 9.96, p = 0.003; ES = 0.98] and CA23DG [F(1,42)= 23.17, p < 0.0001;
ES = 1.49] and thinner hippocampus averaged over all subregions [F(1,42) = 8.49, p = 0.006; ES = 0.90]. Group
averages in subregional thickness are displayed with standard error bars. *p < 0.05. ES, effect size.
FIG. 2. Hippocampal complex unfolding reveals relationship between CB use and subregional hippocampal
morphology in late life. A cortical unfolding procedure was used to produce a flat map of the hippocampal
complex. Regions are color coded according to the strength of the statistical association between CB group and
cortical thickness in individual subregions within the hippocampus and surrounding neocortex. CB, cannabis.
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driving morphological differences between groups),
CA1 and CA23DG thickness were still significantly
lower in CB+ subjects [CA1: F(1,35)= 9.30, p= 0.004,
S =1.03; CA23DG: F(1,35) = 23.95, p < 0.0001, ES =
1.65]. The two groups did not differ in SES either in
early childhood or adulthood.
Additionally, although ‘‘Lifetime Alcohol Use’’ was
not significantly different between the two groups
[t(48) = 0.54, p = 0.6], group models were run an addi-
tional time with this variable added as an covariate to
test whether differences in alcohol use patterns were
driving group differences. However, the pattern of sig-
nificant differences in subregional cortical thickness be-
tween groups remained unchanged [CA23DG [F(1,41)=
25.32, p< 0.0001; ES= 1.37 and CA1 [F(1,41)= 9.67,
p= 0.003; ES= 1.05]. In contrast, there were no group dif-
ferences in the control parietal lobe region between the
two groups [F(1,41)= 0.45, p= 0.51; ES= 0.21]. No rela-
tionship between age of onset of cannabis use or lifetime
cannabis use was found with thickness metrics. Differen-
ces between groups were not statistically significant across
any neuropsychological measures [Memory Encoding
Domain: F(1,42)= 0.90, p= 0.35, ES= 0.29; Delayed
Memory Domain: F(1,42)= 0.94, p= 0.34, ES= 0.30; Pro-
cessing Speed Domain: F(1,42)= 1.33, p= 0.26, ES= 0.36;
Executive Function Domain: F(1,42)= 0.05, p= 0.82,
ES= 0.07]. No neuropsychological domains showed a sig-
nificant relationship with cortical thickness in any subre-
gions. However, CB+ group averages were lower than
CB group averages across all neuropsychological mea-
sures (Fig. 4).
Discussion
These results provide the first evidence of an associa-
tion between early life CB use and later morphology
changes in the medical temporal lobe, several decades
after cessation of usage. Participants who reported
heavy CB use in early life showed thinner cortex in hip-
pocampal subregions CA1, 2, 3, and the DG. Morpho-
logical differences between groups were regionally
specific to CA and DG regions and were not present
in neocortical regions of the MTL, including entorhinal,
perirhinal, and parahippocampal cortices. Additionally,
cortical thickness in parietal cortex, a region relatively
FIG. 4. Neuropsychological domain scores, Z-scaled for CB+ and CBgroups. Domains were created using
the following tests within each domain: Memory Encoding (Buschke-Fuld selective reminding test, consistent
long-term retrieval; Wechsler Memory Scale-II, Logical Memory I and Verbal Paired Associates I), Delayed
Memory (Wechsler Memory Scale: Logical Memory II and Verbal Paired Associates II; Rey–Osterrieth Complex
Figure, Delayed Recall; Buschke-Fuld Selective Reminding Test, Delayed Recall), Processing Speed (Trailmaking
Test, Part A; Stroop Test, Word Reading Speed; Wechsler Adult Intelligence Scale-III Digit Symbol), and Executive
Functioning (Trailmaking Test Part B; Verbal Fluency FAS and Animal Naming tests; Stroop Test, Interference).
Group averages and standard errors are displayed for all neuropsychological test domains. Differences
between the groups were not significant, however, CB+ group averages were less than CB averages across
all domains.
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low in CB1 receptors but still subject to age-related
changes, showed no differences between groups. These
results underscore the persistent nature of adolescent-
induced brain changes due to heavy CB use, and the ris-
ing need to understand how these changes interact with
brain aging.
Our findings of thinner hippocampal cortex restricted
to CA1, 2, 3 and the DG are relevant in relation to the
functional impairment shown in chronic CB users during
adolescence. Hippocampal subregions follow synaptic
projections from the ERC through the DG, CA3, CA2,
and then to Sub with each synaptic connection represent-
ing a specific function in the information processing path-
way.57,58 Hippocampal subregions, CA1, CA3, and the
DG, support the representation and encoding of novel in-
formation, allowing the HC to organize information and
support short-term memory processes.59
In adolescent and early life CB users, memory impair-
ment is one of the most frequent problems observed
with persistent CB use,21 and it may be linked to specific
structural alterations in CA3 and the DG. Although no
differences in neuropsychiatric domain scores were
found in the present study, lower scores in CB users
were noted for every domain (Fig. 4); a larger sample
size in future studies will help elucidate this relationship
more fully.
Neuroimaging investigations on the structural ef-
fects of CB use on the brain have been inconsistent.32
Changes in gray or white matter density have been
reported in different locations in frontal and parietal
lobes without overlapping results across studies.60–62
These discrepancies might be due to heterogeneity in
sample characteristics, individual differences in comor-
bid substance use, amount of consumption, or method-
ological differences in data processing.17,63
Changes in the HC/parahippocampal complex have
often been reported33,62,64,65 and highlights the ratio-
nale behind the present investigation on the MTL,
which was intended to investigate the relationship be-
tween early life CB use and late-life brain morphology.
Although the precise mechanisms underlying the ef-
fects of CB on the HC are not fully understood, animal
studies have shown that THC accumulates in neu-
rons,66 with long-term exposure to THC resulting in
neurotoxic changes in hippocampal microstructure,67
and there is particular concern regarding potential
age-related interaction in the MTL, a brain area with
high susceptibility to age-related morphology changes
in late life.68 Adding to this concern, the fact that sub-
jects in the present study had been rare or abstinent
users for several decades suggests that CB-induced
morphological changes from heavy adolescent expo-
sure may have very long-term negative consequences.
Retrospective assessment of any drug use with no
corroboration is challenging considering the life-long
experiences and exposures among individual subjects.
It is also noted that comparing parietal cortex, which
is larger in size than the HC, is not perfectly matched
to the sensitivity of examining hippocampal subre-
gions. Selection bias is another confound we recognize;
one cannot know for certain if the differences in hippo-
campal atrophy between groups are due to pre-existing
differences before CB use onset.
However, since the results held true after regression
of the variables most likely to reflect baseline differ-
ences between groups (WTAR scores, gender, and
cigarette use) as well as the specificity of results to
CB1-rich brain regions, the findings presented in this
study are not easily attributed to pre-existing group dif-
ferences. Future studies should attempt to reproduce
our CB-dependent effects in larger samples. Currently,
the Adolescent Brain Cognitive Development study
(https://abcdstudy.org) is prospectively following brain
development with the largest long-term study of child
brain development in the United States.
With increased usage, potency, and research indicating
CB affects the HC,31 investigating the long-term effects of
adolescent use in an aging population is essential for un-
derstanding the long-term consequences of heavy, early
life CB exposure. Approximately 9% of persons who ex-
periment with CB will become addicted.69 Our results
provide evidence of neuroanatomical alterations in the
hippocampi of ex-CB users and underscore the impor-
tance of assessing subregional hippocampal morphology.
They also underscore the persistent nature of adolescent-
induced brain changes due to CB use, and the rising need
to understand how these changes interact with brain
aging. Future studies should examine the effects of these
morphological differences longitudinally to uncover the
functional and behavioral implications of these brain
differences.
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